164 related articles for article (PubMed ID: 24810637)
21. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
22. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
[TBL] [Abstract][Full Text] [Related]
23. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
24. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
25. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
26. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
[TBL] [Abstract][Full Text] [Related]
28. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
[TBL] [Abstract][Full Text] [Related]
29. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
30. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
31. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
33. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
34. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
35. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
36. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
37. NKG2D-IL-15 fusion protein encapsulated in N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride retards melanoma growth in mice.
Chen R; Ding Y; Xi J; Lu G; Xiao W; Ding Y; Qian L; Lin Z; Gong W
Transl Cancer Res; 2019 Oct; 8(6):2230-2241. PubMed ID: 35116976
[TBL] [Abstract][Full Text] [Related]
38. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of colon tumor growth by IL-15 immunogene therapy.
He X; Li W; Wang Y; Hou L; Zhu L
Mol Med Rep; 2012 Jan; 5(1):96-102. PubMed ID: 21956355
[TBL] [Abstract][Full Text] [Related]
40. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
